Exploiting tumor‐associated dendritic cell heterogeneity for novel cancer therapies
Exploiting tumor‐associated dendritic cell heterogeneity for novel cancer therapies
复制标题
DOI：
10.1189/jlb.4mr1116-466r
复制
发表时间：
2017-08
影响因子：
5.5
通讯作者：
J. Keirsse;Helena Van Damme;J. V. Van Ginderachter;Damya Laoui
中科院分区：
文献类型：
--
作者：
J. Keirsse;Helena Van Damme;J. V. Van Ginderachter;Damya Laoui
树突状细胞（dc）是存在于包括肿瘤在内的所有组织中的特化apc。它们在协调免疫反应中起着重要作用，并被证明在肿瘤的各种功能状态下发生。在这方面，免疫原性肿瘤相关dc （TADCs）需要启动和维持T细胞依赖的抗癌免疫，而调节性TADCs具有强大的免疫抑制潜力并加速恶性生长。重要的是，最近在小鼠和人类癌症中，肿瘤中DC隔室的异质性已经被解剖，并被证明由发育不同的亚群组成，包括传统DC (cDC)1、cDC2和单核细胞来源的DC （Mo - DCs）。在产生针对癌症的治疗性免疫的努力中，tdac是一个重要的靶点，了解tdac异质性的复杂性可能对针对特定tdac亚群或其前体的治疗干预很重要。因此，这篇综述讨论了不同的ttac亚群的不同功能特化。
Dendritic cells (DCs) are specialized APCs present in all tissues, including tumors. They play a major role in orchestrating immune responses and were shown to occur in various functional states in tumors. In this respect, immunogenic tumor‐associated DCs (TADCs) are required to initiate and sustain T cell‐dependent anti‐cancer immunity, whereas regulatory TADCs harbor robust immunosuppressive potential and accelerate malignant growth. Importantly, the heterogeneity of the DC compartment in tumors has been dissected recently in murine and human cancers and was shown to consist of developmentally distinct subsets, including conventional DC (cDC)1, cDC2, and monocyte‐derived DCs (Mo‐DCs). TADCs constitute an essential target in efforts to generate therapeutic immunity against cancer, and the understanding of the complexity of the TADC heterogeneity might prove important for therapeutic interventions targeted at specific TADC subsets or their precursors. Hence, this review addresses the differential functional specializations of ontogenically distinct TADC subsets.